KR20230013102A - 아밀로이드증의 치료 - Google Patents

아밀로이드증의 치료 Download PDF

Info

Publication number
KR20230013102A
KR20230013102A KR1020227044559A KR20227044559A KR20230013102A KR 20230013102 A KR20230013102 A KR 20230013102A KR 1020227044559 A KR1020227044559 A KR 1020227044559A KR 20227044559 A KR20227044559 A KR 20227044559A KR 20230013102 A KR20230013102 A KR 20230013102A
Authority
KR
South Korea
Prior art keywords
unsubstituted
substituted
compound
alkyl
amyloidosis
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
KR1020227044559A
Other languages
English (en)
Korean (ko)
Inventor
케빈 듀언 번커
아흐메드 아브디 사마타르
죠셉 로버트 핀치맨
피터 친후아 후앙
Original Assignee
리커리엄 아이피 홀딩스, 엘엘씨
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 리커리엄 아이피 홀딩스, 엘엘씨 filed Critical 리커리엄 아이피 홀딩스, 엘엘씨
Publication of KR20230013102A publication Critical patent/KR20230013102A/ko
Withdrawn legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4965—Non-condensed pyrazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A61K31/573—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/69—Boron compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/05—Dipeptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/07—Tetrapeptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Steroid Compounds (AREA)
  • External Artificial Organs (AREA)
KR1020227044559A 2020-05-19 2021-05-17 아밀로이드증의 치료 Withdrawn KR20230013102A (ko)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202063027194P 2020-05-19 2020-05-19
US63/027,194 2020-05-19
PCT/US2021/032808 WO2021236543A1 (en) 2020-05-19 2021-05-17 Treatment for amyloidosis

Publications (1)

Publication Number Publication Date
KR20230013102A true KR20230013102A (ko) 2023-01-26

Family

ID=78708017

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020227044559A Withdrawn KR20230013102A (ko) 2020-05-19 2021-05-17 아밀로이드증의 치료

Country Status (12)

Country Link
US (1) US20230210846A1 (https=)
EP (1) EP4138837A4 (https=)
JP (1) JP2023527741A (https=)
KR (1) KR20230013102A (https=)
CN (1) CN116133661A (https=)
AU (1) AU2021273731A1 (https=)
BR (1) BR112022023486A2 (https=)
CA (1) CA3183746A1 (https=)
IL (1) IL298297A (https=)
MX (1) MX2022014468A (https=)
TW (1) TW202207931A (https=)
WO (1) WO2021236543A1 (https=)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2023114877A1 (en) * 2021-12-15 2023-06-22 Recurium Ip Holdings, Llc Triple therapy combinations of bcl-2 inhibitors, wee-1 inhibitors and other chemotherapeutic agents

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20200108301A (ko) * 2018-01-10 2020-09-17 리커리엄 아이피 홀딩스, 엘엘씨 벤즈아미드 화합물
WO2019199899A1 (en) * 2018-04-09 2019-10-17 Case Western Reserve University Bioink and crosslinkable support medium for printing
US10659731B2 (en) * 2018-04-10 2020-05-19 Facebook, Inc. Automated cinematic decisions based on descriptive models
CA3095513A1 (en) * 2018-04-10 2019-10-17 DDP Specialty Electronic Materials US, Inc. Dispenser for can with fixed valve stem housing

Also Published As

Publication number Publication date
CN116133661A (zh) 2023-05-16
MX2022014468A (es) 2023-02-09
IL298297A (en) 2023-01-01
JP2023527741A (ja) 2023-06-30
BR112022023486A2 (pt) 2023-01-10
EP4138837A4 (en) 2024-05-22
CA3183746A1 (en) 2021-11-25
AU2021273731A1 (en) 2022-12-15
EP4138837A1 (en) 2023-03-01
WO2021236543A1 (en) 2021-11-25
TW202207931A (zh) 2022-03-01
US20230210846A1 (en) 2023-07-06

Similar Documents

Publication Publication Date Title
JP7750526B2 (ja) 組み合わせ
KR20230010729A (ko) 단독 요법 및 병용 요법
EP4069225A1 (en) Combinations
JP7631348B2 (ja) 組み合わせ
JP7794448B2 (ja) 組み合わせ
KR20230013102A (ko) 아밀로이드증의 치료
AU2020404995A1 (en) Combinations
KR20230007360A (ko) 복합제
JP2023545498A (ja) Ｂｃｌ－２阻害剤と化学療法剤との組み合わせ
RU2840819C1 (ru) Комбинации
WO2021127036A1 (en) Combinations

Legal Events

Date Code Title Description
PA0105 International application

St.27 status event code: A-0-1-A10-A15-nap-PA0105

PG1501 Laying open of application

St.27 status event code: A-1-1-Q10-Q12-nap-PG1501

PC1203 Withdrawal of no request for examination

St.27 status event code: N-1-6-B10-B12-nap-PC1203